What's new? Log in Free sign up

Filing search / Innovation Pharmaceuticals Inc. / "Safety"

Search information

Innovation Pharmaceuticals Inc.

Companies

"Safety"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

105 results

Newest first Best match first

IPIX Innovation Pharmaceuticals Inc.

Quarterly report

30, 2023. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES None ITEM 3. DEFAULTS UPON SENIOR SECURITIES None ITEM 4. MINE SAFETY DISCLOSURES None

20 Nov 23

4:05pm

IPIX Innovation Pharmaceuticals Inc.

3 planned, contingent upon sufficient funding Inflammatory Bowel Disease (IBD) Phase 2 UP/UPS Proof of Concept Study (completed) Phase 1 Safety … , and an IND is necessary to begin human safety and efficacy trials (Phase 1, 2 and 3). GOVERNMENT REGULATION Our operations and activities

28 Sep 23

9:00am

IPIX Innovation Pharmaceuticals Inc.

Quarterly report

Safety/toleration/PK of oral dosage form (completed) ABSSSI (Acute Bacterial Skin and Skin Structure Infection) Phase 2 (completed) We have no product … SECURITIES None ITEM 3. DEFAULTS UPON SENIOR SECURITIES None ITEM 4. MINE SAFETY DISCLOSURES None ITEM 5. OTHER INFORMATION None ITEM 6. EXHIBITS

15 May 23

8:01am

IPIX Innovation Pharmaceuticals Inc.

Quarterly report

Study (completed) Phase 1 Safety/toleration/PK of oral dosage form (completed) ABSSSI (Acute Bacterial Skin and Skin Structure Infection) Phase 2 … SECURITIES None ITEM 3. DEFAULTS UPON SENIOR SECURITIES None ITEM 4. MINE SAFETY DISCLOSURES None ITEM 5. OTHER INFORMATION None ITEM 6. EXHIBITS

10 Nov 22

4:06pm

IPIX Innovation Pharmaceuticals Inc.

planned, contingent upon sufficient funding Inflammatory Bowel Disease (IBD) Phase 2 UP/UPS Proof of Concept Study (completed) Phase 1 Safety … (IND) application with the FDA, and an IND is necessary to begin human safety and efficacy trials (Phase 1, 2 and 3). GOVERNMENT REGULATION Our

28 Sep 22

4:00pm

Quarterly report

13 May 22

4:07pm

s6yw0c 3ibjdgun22

Quarterly report

14 Feb 22

4:00pm

Quarterly report

9 Nov 21

1:44pm

yvrgalrj yv739epyd3

27 Sep 21

4:16pm

Quarterly report

13 May 21

8:00am

Quarterly report

22 Feb 21

11:19am

141nbcxp3dfh vl

Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives

FDA Grants IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals’ Brilacidin for Treating COVID-19

Entry into a Material Definitive Agreement

Innovation Pharmaceuticals Announces Overseas Regulatory Filing Submitted For COVID-19 Clinical Study

Quarterly report

16 Nov 20

9:00am

Regulation FD Disclosure

Regulation FD Disclosure

5dvtt0emf8b89r42vr

Innovation Pharmaceuticals Announces Pre-IND Meeting Request Granted by FDA for the Study of Brilacidin for the Treatment of COVID-19

kgb 0qvdz8e5ivt85749

Laboratory Testing of Brilacidin for COVID-19 in Combination with Remdesivir Reduces Viral Load by Nearly 100 Percent

Prev
1
2
3
4
5
...
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.